Fostemsavir Tromethamine Patent Expiration
Fostemsavir Tromethamine was first introduced by Viiv Healthcare Co
Fostemsavir Tromethamine Patents
Given below is the list of patents protecting Fostemsavir Tromethamine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rukobia | US8168615 | Prodrugs of piperazine and substituted piperidine antiviral agents | Jul 13, 2029 | Viiv Hlthcare |
| Rukobia | US7745625 | Prodrugs of piperazine and substituted piperidine antiviral agents | Nov 19, 2027 | Viiv Hlthcare |
| Rukobia | US8461333 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | Feb 25, 2025 | Viiv Hlthcare |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Fostemsavir Tromethamine's patents.
Latest Legal Activities on Fostemsavir Tromethamine's Patents
Given below is the list recent legal activities going on the following patents of Fostemsavir Tromethamine.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Term Extension Certificate Critical | 11 Mar, 2024 | US8168615 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Oct, 2023 | US8168615 |
| Notice of Final Determination -Eligible | 03 Oct, 2023 | US8168615 |
| FDA Final Eligibility Letter Critical | 10 May, 2023 | US8168615 |
| Second letter to regulating agency to determine regulatory review period | 16 Feb, 2022 | US8168615 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Nov, 2021 | US7745625 |
| Letter from FDA or Dept of Agriculture re PTE application | 01 Mar, 2021 | US8168615 |
| Initial letter Re: PTE Application to regulating agency | 02 Dec, 2020 | US8168615 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Sep, 2020 | US8461333 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Oct, 2019 | US8168615 |
Fostemsavir Tromethamine's Family Patents
